Nagoya University · Medicine
Professor Kazuyuki Mizuno's research lab specializes in oncology and immunotherapy, with a focus on overcoming multidrug resistance in cancer and improving treatment outcomes in hepatocellular carcinoma (HCC). The lab investigates the mechanisms of drug resistance, particularly in ovarian and liver cancers, and evaluates the efficacy and safety of immune checkpoint inhibitors (ICIs), including rechallenge strategies after immune-related adverse events (irAEs). A key area of interest is the prognostic value of liver function assessment tools such as ALBI grade in B-type hepatitis-related HCC, offering refined patient stratification beyond traditional classifications like Child-Pugh. The lab also explores repurposed immunosuppressive agents as modulators of multidrug resistance, aiming to enhance chemotherapy efficacy.
Figures are computed from collected data and may differ slightly.
It has recently been reported that an immunosuppressive agent, cyclosporin A, shows a potent overcoming effect on multidrug resistance (MDR). We studied the presence of such a modulating effect of cyclosporin analogues and other immunosuppressive agents, FK506 and mizoribine, in human multidrug-resistant ovarian cancer cells (TAOV/A0.2). The intensity of the overcoming effect of cyclosporin analogues against adriamycin resistance was found to be in the other of cyclosporin D greater than A great
Pretreatment proteinuria predicts a poorer prognosis in patients with unresectable HCC treated with lenvatinib or atezolizumab plus bevacizumab but not in those treated with sorafenib.
ICI retreatment after severe irAEs demonstrated a manageable safety profile and promising efficacy, even in patients with grade ≥3 irAEs. ICI retreatment may be a viable option for patients with limited alternatives, particularly those showing favorable antitumor responses at initial treatment.
Immune checkpoint inhibitors (ICIs), which target immune regulatory molecules such as cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1, are widely used as standard treatments for various cancer types. However, by overcoming T-cell suppression, they can also trigger immune-related adverse events (irAEs) that may necessitate treatment discontinuation. Rechallenging with an ICI after irAE resolution remains a clinical dilemma. This review evaluates current evidence on the e
B型肝炎を背景とする肝細胞癌症例の肝機能評価におけるALBI gradeの予後予測能を，Child-Pugh分類と比較した．HBs抗原陽性の初発肝細胞癌の生存率はALBI grade・Child-Pugh分類いずれでも有意差をもって分別されたが，5年・10年生存率はALBI grade 1で77.8%・64.8%，Child-Pugh Aで60.8%・48.5%と前者で有意に高かった（p=0.004）．Child-Pugh Aに限って検討すると，5年・10年生存率はALBI grade 1で78.8%・65.7%，grade 2で27.9%・17.0%であり肝機能の面からみた予後を分別した（p＜0.001）．ALBI gradeはB型肝炎由来の肝細胞癌においても予後予測に有用であり，Child-Pugh分類と比べさらに肝機能の良い症例の選択が可能な評価法と考えられた．
Open papers in the app to read, cite, and organize with AI.
